Skip to main content
Premium Trial:

Request an Annual Quote

Genuity Science, Emory Team on Biomarker Discovery for Neurodegenesis

NEW YORK – Genuity Science said Thursday that it is teaming with Emory University to develop a population clinicogenomic database to support biomarker and drug target discovery and validation. The partnership initially will focus on neurogenerative conditions, including Alzheimer's and Parkinson's diseases.

"Emory fits perfectly within our strategy of combining detailed clinical and longitudinal data from large-scale, powered cohorts of many thousands of patients with whole-genome sequence and other omic data to provide discoveries beyond the usual suspects of disease genes," Jeff Gulcher, chief scientific officer of Boston-based Genuity Science, said in a statement.

"We know there are dozens of genes contributing to risk of these conditions. I believe there's huge scope to improve drug discovery, development, and clinical trials stemming from the insights Genuity hopes to derive from this research," added Emory neurology Chairman Allan Levey. "Our collaboration with Genuity provides us with a potential opportunity to greatly accelerate our academic research efforts for the benefit of our patient population by including whole-genome sequence data to our cohort."

Genuity, formerly known as WuXi NextCode, offers contract genomics and artificial intelligence-driven data sourcing and data analytics services to the biopharmaceutical industry to support drug discovery and development. In October, the firm announced a collaboration with Ionis Pharmaceuticals to use genomics to develop new antisense therapeutics.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.